Abstract
The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Keywords: HLA-B27, hypothesis, homodimers, T cells
Current Molecular Medicine
Title: The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells
Volume: 4 Issue: 1
Author(s): Louise H. Boyle, Jane C. Goodall and J. S. Hill Gaston
Affiliation:
Keywords: HLA-B27, hypothesis, homodimers, T cells
Abstract: The MHC class I molecule, HLA-B27 can be expressed as a number of non-conventional forms, in addition to conventional HLA-B27 heterodimers presenting peptide. This has lead to new avenues of research to explain the association of this molecule with SpA. Surprisingly, HLA-B27 transgenic animal models implicated CD4+ T cells, which conventionally interact with MHC class II molecules, not MHC class I molecules, in the pathogenesis of SpA. One hypothesis to explain these finding is that non-conventional forms of HLA-B27, specifically HLA-B27 homodimers, might mimic MHC class II molecules and be recognised by CD4+ T cells. We investigated whether CD4+ T cells from AS patients can interact with HLA-B27, discovering that indeed CD4+ T cells can interact with various forms of HLA-B27. Here we discuss how such interactions between HLA-B27 and CD4+ T cells could occur in vivo and potential contributions of such interactions to the pathogenesis of SpA.
Export Options
About this article
Cite this article as:
Boyle H. Louise, Goodall C. Jane and Gaston S. Hill J., The Recognition of Abnormal Forms of HLA-B27 by CD4+ T Cells, Current Molecular Medicine 2004; 4 (1) . https://dx.doi.org/10.2174/1566524043479257
DOI https://dx.doi.org/10.2174/1566524043479257 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Peptides as Tight Junction Modulators
Current Pharmaceutical Design Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Human- and Virus-Encoded microRNAs as Potential Targets of Antiviral Therapy
Mini-Reviews in Medicinal Chemistry The Role of Bioreactors in Cartilage Tissue Engineering
Current Stem Cell Research & Therapy Gene Assessment and Sample Classification for Gene Expression Data Using a Genetic Algorithm / k-nearest Neighbor Method
Combinatorial Chemistry & High Throughput Screening Prospects for the Therapeutic Application of Lentivirus-Based Gene Therapy to HIV-1 Infection
Current Gene Therapy Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Current Diabetes Reviews Dendrimers: A Class of Polymers in the Nanotechnology for the Delivery of Active Pharmaceuticals
Current Pharmaceutical Design Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry An Atypical Case of Fulminant Interstitial Pneumonitis Induced by Carbamazepine
Current Drug Safety Editorial from Editor-in-Chief (The Role of Statins in the Intensive Care Unit)
Current Respiratory Medicine Reviews Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology Intramolecular Haloetherification and Transannular Hydroxycyclization of Alkenes. A Synthetic Methodology to Obtain Polycyclic Ethers and Amines
Current Organic Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets